Metabolic Imaging with FDG: A Primer
Metabolic Imaging with FDG: A Primer
复制标题
FDG 代谢成像：入门
作者：
D. Delbeke;W. Martin
影像技术的快速发展对放射科医生和临床医生来说都是一个挑战，他们必须以最小的成本整合这些技术以获得最佳的患者护理和结果。使用氟脱氧葡萄糖（FDG）进行功能成像的多种适应症现已在神经病学、心脏病学和肿瘤学领域得到广泛接受，包括良恶性病变的区分、恶性病变的分期、恶性复发的检测和治疗的监测。整合正电子发射断层扫描(PET)-CT系统获得的解剖和分子图像（计算机断层扫描[CT]和FDG）的融合，在时间上是顺序的，但不需要将患者移出成像台，允许解剖和分子图像的最佳共同配准，从而导致精确的衰减校正和精确的病变解剖定位，并增加代谢。这项强大的技术为诊断和治疗应用提供了一种有价值的新工具。由于CT和FDG PET图像病变检测的改善，FDG摄取的生理性和病理性病灶的更好区分，以及FDG摄取的恶性病灶的更好定位，大约50%的患者的诊断准确性得到了提高。这项新技术通过指导进一步治疗，影响了10%-20%病例的管理。有前景的临床应用包括引导活检到肿瘤的代谢活跃部位，指导手术和计划调强放射治疗。此外，新的PET放射性药物正在出现，用于FDG有局限性的适应症。一些新的PET示踪剂被标记为18F，这对于商业销售来说有一个实际的半衰期。在过去的几年中，FDG的临床适应症急剧扩大，综合多模态成像系统和新型PET示踪剂的快速技术发展进一步扩大了视野。
The rapid advances in imaging technologies are a challenge for both radiologists and clinicians who must integrate these technologies for optimal patient care and outcomes at minimal cost. Multiple indications for functional imaging using fluorodeoxyglucose (FDG) are now well accepted in the fields of neurology, cardiology, and oncology, including differentiation of benign from malignant lesions, staging of malignant lesions, detection of malignant recurrence, and monitoring of therapy.The fusion of anatomic and molecular images (computed tomography [CT] and FDG) obtained with integrated positron emission tomography (PET)-CT systems, sequentially in time but without moving the patient from the imaging table, allows optimal co-registration of anatomic and molecular images, leading to accurate attenuation correction and precise anatomic localization of lesions with increased metabolism. This powerful technology provides a valuable new tool for diagnostic and therapeutic applications. The diagnostic accuracy is improved in approximately 50% of patients because of improvement of lesion detection on both CT and FDG PET images, better differentiation between physiologic and pathological foci of FDG uptake, and better localization of malignant foci of FDG uptake. This new technology affects the management of 10%-20% of cases by guiding further therapy. Promising clinical applications include guiding biopsy to the metabolically active sites of tumors, guiding surgery, and planning intensity-modulated radiation therapy. In addition, new PET radiopharmaceuticals are emerging for indications for which FDG has limitations. Some of the new PET tracers are labeled with 18F, which has a practical half-life for commercial distribution.In the past few years, the clinical indications for FDG have broadened dramatically, and the rapid technical developments of integrated multimodality imaging systems and new PET tracers further extend the horizon.
登录
查看更多内容
DOI：
10.1016/s0360-3016(00)80050-4
发表时间：
2002
期刊：
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
影响因子：
--
作者：
Y. Erdi;K. Rosenzweig;A. Erdi;H. Macapinlac;Y. Hu;L. Braban;J. Humm;O. Squire;C. Chui;S. Larson;E. Yorke
通讯作者：
Y. Erdi;K. Rosenzweig;A. Erdi;H. Macapinlac;Y. Hu;L. Braban;J. Humm;O. Squire;C. Chui;S. Larson;E. Yorke
影响因子：
56.9
作者：
FLIER, JS;MUECKLER, MM;LODISH, HF
通讯作者：
LODISH, HF
影响因子：
6.6
作者：
Price, DT;Coleman, RE;deGrado, TR
通讯作者：
deGrado, TR
影响因子：
5.3
作者：
Munley, MT;Marks, LB;Coleman, RE
通讯作者：
Coleman, RE